期刊文献+

7种β-微管蛋白同型在非小细胞肺癌中的表达及其和紫杉类药物敏感性的研究 被引量:3

Study on expression of 7 kinds of β-tubulin isotypes in non small cell lung cancer and its correlation with taxane sensitivity
下载PDF
导出
摘要 目的探讨7种β-微管蛋白同型mRNA及Ⅲ型β-微管蛋白在非小细胞肺癌(Non small cell lung cancer,NSCLC)中的表达,及其表达与紫杉类药物敏感性的关系。方法收集55例未经化疗的不能手术的转移性或复发晚期NSCLC患者肿瘤组织标本,一线均采用铂类联合紫杉类药物的双药化疗方案治疗,两个周期后评估疗效,将完全缓解(CR)和部分缓解(PR)归为紫杉类敏感组,疾病稳定(SD)为紫杉类次敏感组,疾病进展(PD)为紫杉耐药组。采用RT-RCR方法检测肿瘤组织中7种β-微管蛋白同型mRNA的表达;采用免疫组织化学法(IHC)方法检测Ⅲ型β-微管蛋白的表达。分析各组标本中7种β-微管蛋白同型的mRNA表达水平和Ⅲ型β-微管蛋白的表达阳性率,并与紫杉类的敏感性进行相关性分析。结果在55例NSCLC标本中,均可检测到7种β-微管蛋白同型mRNA的表达,以Ⅱ型和V型β-微管蛋白相对表达量最高。Ⅲ型β-微管蛋白的mRNA表达在紫杉敏感组和紫杉次敏感组均低于紫杉耐药组(P<0.05);而其他6种β-微管蛋白同型(I,Ⅱ,Iva,IVb,V,VI)的mRNA表达在三组均无统计学差异(P>0.05)。IHC结果显示,Ⅲ型β-微管蛋白在紫杉敏感组,紫杉次敏感组的表达阳性率分别为16.67%(3/18),20.00%(4/20),均低于紫杉耐药组52.94%(9/17),差异具有统计学意义(P<0.05);而Ⅲ型β-微管蛋白在紫杉敏感组和紫杉次敏感组的表达阳性率无统计学差异(P>0.05)。结论 7种β-微管蛋白同型在NSCLC肿瘤组织中均可检测到mRNA表达,其中Ⅲ型β-微管蛋白的mRNA和蛋白表达与紫杉类药物的敏感性相关,高表达者显示出对紫杉类药物的耐药。 Objective To detect the expressions of 7 kinds of β-tubulin isotypes in patients with non small cell lung cancer ( NSCLC) and the correlation with taxane sensitivity. Methods 55 tumor tissue specimens were collected from patients with chemo-naive and unoperable metastatic or recurrent NSCLC, who accepted regimen of platinum plus taxane in first line therapy. The efficacy was assessed after two cycle therapy. 55 patients were divided into three groups according to their efficacy. Patients with CR or PR were classed as the taxane sensitive group, and patients with SD were the taxane less sensitive group, and patients with PD were the taxane resistance group. The ex-pressions of mRNA of 7β-tubulin isotypes in tumor tissues were detected by RT-RCR. The expression ofβⅢ-tubulin protein was detected by IHC. The expressions of 7 β-tubulin isotypes and its correlation with taxane sensitivity were anlyzed. Results The expression of mRNA of 7 β-tubulin isotypes were all detected in 55 patients with NSCLC. ΒⅡ-tubulin and βⅣ-tubulin were the highest ones. The expression of mRNA of βⅢ-tubulin in the taxane sensitive group and the taxane less sensitive group were both lower than that in the taxane resistance group (P0. 05). The expressions of β Ⅲ-tubulin in the taxane sensitive group and the taxane less sensitive group were 16. 67% (3/18) and 20. 00% (4/20) respectively, which were lower than that in the taxane resistance group (52. 94%, 9/17, P〈0. 05). Conclusion The mRNA expressions of 7 β-tubulin isotypes can be all detected in tumor tissue of NSCLC, in which the expressions of mRNA and protein of βⅢ-tubulin show a correlation with taxane sensitivity. The high expression of βⅢ-tubulin shows cer-tain resistance to taxanes.
出处 《临床肺科杂志》 2015年第3期394-398,共5页 Journal of Clinical Pulmonary Medicine
基金 南京市卫生局医学科技发展项目(No YKK09146)
关键词 β-微管蛋白同型 非小细胞肺癌 紫杉类药物 药物敏感性 β-tubulin isotype non-small cell lung cancre taxanes drug sensitivity
  • 相关文献

参考文献10

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [ J ]. CA Cancer J Clin, 2012, 62(1) : 10 -29. 被引量:1
  • 2Xiao H, Verdier-Pinard P, Fernandez-Fuentes N, et al. Insights into the mechanism of microtubule stabilization by Taxol [ J]. Proc Natl Acad Sci, 2006, 103(27) :10166 -10173. 被引量:1
  • 3Roque DM, Buza N, Glasgow M, et al. Class 11 -tubulin over- expression within the tumor microenvironment is a prognostic bio- marker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel[ J ]. Clin Exp Metastasis, 2014, 31(1):101-110. 被引量:1
  • 4Wang Y, Sparano JA, Fineberg S, et al. High expression of class m -tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen re- ceptor-negative breast cancer[ J]. Clin Breast Cancer, 2013, 13 (2) : 103 - 108. 被引量:1
  • 5Sve P, Mackey J, Isaac S, et al. Class [ beta-tubulin expres- sion in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel[ J]. Mol CancerTher, 2005, 4(12): 2001 -2007. 被引量:1
  • 6El-Kareh AW, Labes RE, Secomb TW. Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs [J]. AAPS J, 2008, 10(1) :15 -34. 被引量:1
  • 7Cucchiarelli V, Hiser L, Smith H, et al. 13-Tubulin Isotype Clas- ses 1I and V expression patterns in Nonsmall Cell Luang carcino- mas[J]. Cell Motil. Cytoskeleton, 2008, 65:675 -685. 被引量:1
  • 8Wehbe H, Kearney CM, Pinney KG. Combretastatin A-4 resist- ance in H460 human lung carcinoma demonstrates distinctive alter- ations in beta-tubulin isotype expression [ J ]. Anticancer Res,2005, 25(6B) : 3865 -3870. 被引量:1
  • 9Zhang Y, Yang H, Liu J, et al. High expression levels of class 111 13-tubulin in resected non-small cell lung cancer patients are pre- dictive of improved patient survival after vinorelbine-based adjuvant chemotherapy[ J ]. Oncol Lett, 2013, 6 ( 1 ) : 220 - 226. 被引量:1
  • 10Zhang HL, Ruan L, Zheng LM, et al. Association between class ] 13-tubulin expression and response to paelitaxel/vinorebine- based chemotherapy for non-small cell lung cancer: a meta-analysis EJ]. Lung Cancer, 2012, 77(1): 9-15. 被引量:1

同被引文献21

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部